PLEASANTON, Calif., Aug. 26, 2011 /PRNewswire/ -- QuantaLife, Inc., a pioneer in the area of digital PCR, is embarking on a seven-city tour to give scientists the opportunity to evaluate the capabilities of digital PCR and see the QuantaLife Droplet Digital PCR (ddPCR™) System in action. The tour will start on Monday, September 12 in Boston and finish up in San Francisco on Friday, September 23.
The QuantaLife ddPCR System claims to be the world's most precise quantitative PCR system. It introduces the next generation of PCR by providing absolute quantification of targeted nucleic acid molecules, a capability that could play a significant role in the development of companion diagnostics and the emergence of personalized medicine – a role that has long been held by real-time PCR.
The Droplet Digital PCR Road Show will take place at the following cities from September 12 through September 23:
The featured speaker is Dr. Jason H. Bielas of the Fred Hutchinson Cancer Research Center who will present his results from the use of the ddPCR system in the study of mutation detection in clinical samples. Breakout sessions will also be held on the use of ddPCR for sensitive detection of rare mutants, measurement of copy number, and gene expression. A ddPCR system will be available for demonstration.
There is no charge for attendees. Details and registration information are available at www.QuantaLife.com or by calling (650) 823-6366. Space is limited, and early registration is strongly encouraged.
The QuantaLife Droplet Digital PCR system was introduced last November at the 60th Annual American Society of Human Genetics Meeting and was recognized recently with the 2011 North American Frost & Sullivan Award for New Product Innovation.
QuantaLife has developed the 3rd generation of PCR technology that quantifies DNA molecules by Droplet Digital™ PCR. Droplet Digital PCR provides an absolute measure of target molecules with unrivaled sensitivity and precision. The company's mission is to provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|SOURCE QuantaLife, Inc.|
Copyright©2010 PR Newswire.
All rights reserved